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Accuracy of contrast-enhanced CT and predictive factors for extracapsular spread in 1 
Unknown Primary Head and Neck Squamous Cell Cancer 2 
 3 
Introduction 4 
Pathologically proven extracapsular spread (ECS) in node-positive head and neck squamous 5 
cell carcinoma (HNSCC) is associated with increased rates of locoregional recurrence, distant 6 
metastasis and decreased rates of overall survival. It is found in up to 50% of neck 7 
dissections in clinically and radiologically node-positive necks 1. Its prognostic value may be 8 
modulated based on subsite and p16/high risk HPV (HR-HPV) positivity. In the post-9 
operative period when ECS is histologically confirmed, adjuvant chemoradiotherapy has 10 
been shown to improve overall survival compared to radiotherapy alone2.  Ideally, if it was 11 
identified at the pre-treatment stage it would allow appropriate counselling and therapy 12 
planning. When there is probable ECS on initial staging, it may be preferable to proceed to 13 
radical chemoradiotherapy rather than primary surgery. This avoids the increased morbidity 14 
of tri-modality management. 15 
 16 
The range of sensitivities and specificities for cross-sectional imaging in predicting ECS is 43-17 
80 % and 54-98% respectively. The cohort most commonly studied is oral cavity squamous 18 
cell cancer (SCC) patients in whom surgical staging is more commonly performed and where 19 
neck dissection histology is therefore readily available for analysis. Necrosis on imaging is 20 
one of the more commonly noted predictors of ECS3-5. Other radiological features such as 21 
irregular nodal borders, perinodal fat stranding, size, loss of fat planes and adjacent 22 
structure invasion have also been explored. Radiographically determined ECS is an 23 
independent prognosticator of poor distant disease control and survival in locally advanced 24 
oropharyngeal SCC6 although Maxwell et. al. and Chai et. al. concluded that CECT was not 25 
reliable for ECS prediction in a p16 positive and mixed cohort of HNSCC patients 26 
respectively7,8. 27 
Disease presentation with a metastatic cervical node is relatively common in HNSCC and the 28 
primary mucosal site is often detected during subsequent workup.  However, around 2-9% 29 
of patients exhibiting neck lymph node metastasis from HNSCC have an occult primary 30 
cancer9, that is, no primary site is identified despite extensive diagnostic scrutiny. The 31 
investigative pathway includes clinical examination, CT scan +/- MRI scan and PET-CT scan, 32 
examination under anaesthetic (EUA), tonsillectomy and targeted biopsies of potential 33 
primary sites. In unknown primary cancer, there is no primary tumour “T” stage or surgical 34 
margins to help with prognostication and treatment planning and detection of ECS, a known 35 
independent prognostic factor for survival in these patients,10 is crucial for management.   36 
 37 
The aim of this study was to assess the accuracy of contrast-enhanced CT (CECT) at 38 
predicting ECS and to determine what imaging and clinicopathological features are 39 
associated with ECS in an UPHNSCC cohort.   40 
 41 
42 
Materials and Methods 43 
Study Population 44 
33 patients were identified with true UPHNSCC – negative primary sites on CT/MRI, PET/CT, 45 
EUA, tonsillectomy and biopsies. These patients underwent comprehensive neck dissection 46 
as their primary treatment and were retrospectively identified from a central MDT database 47 
between January 2011 and December 2015. 2 patients were excluded as they had not had a 48 
contrast-enhanced CT performed pre-operatively within 10 weeks of surgery.  All had 49 
unilateral neck disease.  The following information was recorded: demographics, 50 
clinicopathological details including HPV status, pathological nodal stage, (UICC TNM 7th 51 
edition applied in this time period), whether core biopsy performed and adjuvant therapy.   52 
CT Examinations 53 
Contrast enhanced CT of the neck was performed across 6 institutions on 12 CT scanners. 54 
Scanning at these sites was performed with 125 ml of IV contrast medium (Omnipaque 300 55 
(GE Healthcare)) injected as a split bolus: typically 75 ml at 2 ml/sec followed by 50 ml at 2 56 
ml/sec and the neck scanned with arms down at 100 secs after the start of injection. Images 57 
were obtained with between 16 and 128 detectors at 120 kVp, 50-300 mAs, with rotation 58 
time of 0.5-0.75 secs, pitch of 0.67-0.83 and slice width of 0.5-1.25 mm. All images were 59 
retrieved using the commercially available picture archive communication system 60 
(Carestream PACS (Rochester NY)) and evaluated at 3 mm thickness using multiplanar 61 
reconstructions. 62 
Following creation of an anonymous patient list on PACS, two head and neck consultant 63 
radiologists (“A and B”) with 5 and 15 years experience, reviewed each CT scan without 64 
prior knowledge of histopathology findings, original radiology report or adjuvant treatment.  65 
Each observer made an independent blinded dichotomous assessment regarding presence 66 
or absence of ECS in the largest radiologically involved node at each diseased nodal level (I-67 
V). Assessment was done by nodal level to match the resolution of histology reports.  68 
Subsequently, in consensus, these nodes were assessed for the following: largest diameter 69 
in any plane, loss of sharp margin - edge of the node being indistinct at any point (Figure 1), 70 
haziness in adjacent fat - stranding and increased density in the surrounding adipose tissue 71 
(Figure 2),  internal necrosis as evidenced by central low density and loss of fat plane with 72 
adjacent structures such as sternocleidomastoid muscle.  73 
Statistical analysis 74 
Accuracy of independent binary assessment for presence or absence of ECS was assessed at 75 
the nodal level with interobserver agreement determined with weighted kappa. Fisher’s 76 
exact test and unpaired student’s t test were utilised where appropriate, to compare the 77 
imaging and clinicopathological findings and presence of histological ECS using the largest 78 
involved node per patient. Logistic regression was then performed to determine 79 
independent predictors of ECS and to quantify the effect sizes. All analyses were done using 80 
Minitab (version 18) at a 5% significance level.  81 
Ethical considerations 82 
Research ethics committee advice was sought using the online tool from the NHS health 83 




Patient details 88 
Of 31 patients, 23 were male, and 8 female, with mean age 58 years (SD 8 years, range 41-89 
69 years). CECT was performed at a mean of 40 days (SD 13 days, range 13-68 days) prior to 90 
neck dissection. Nine patients had high-risk HPV (HPV 16) identified using in-situ 91 
hybridisation, nine were HR-HPV negative while 13 did not have p16 status or HPV status 92 
assessed at the time of the analysis. 24 patients had undergone core biopsy of one of the 93 
involved nodes for tissue diagnosis, the remainder were diagnosed with fine needle 94 
aspiration (FNA). Nineteen patients had adjuvant chemoradiotherapy and 6 had 95 
radiotherapy alone. 96 
Reader Results 97 
39 cervical node levels contained pathological looking nodes on CECT.  ECS was suspected in 98 
29 and 27 levels by observer 1 and 2 respectively. Histopathological ECS was confirmed in 99 
26 levels in 23 patients. This involved level I (1), level II (17), level III (7), level IV (0) and level 100 
V (1). The sensitivity of subjective assessment for ECS by nodal level was 81-85% (CI 65-93%) 101 
and specificity 46-54% (CI 19-81%). Positive predictive value was 76-78% and negative 102 
predictive value 58-60%. There was excellent inter-rater agreement (kappa=0.874).  103 
Univariate analysis 104 
On univariate analysis, based on the largest abnormal node per patient, haziness in the 105 
adjacent fat (p 0.02) and longest nodal dimension 30mm (p 0.01) were statistically 106 
significant radiological features predictive of ECS, while patient age (p 0.006) and 107 
pathological nodal status (N2/3 versus N1) (p 0.002) were statistically significant 108 
clinicopathological findings. (Table 1) 109 
Loss of sharp margin, nodal necrosis, loss of fat plane with adjacent structures, sex of the 110 
patient or preceding core biopsy of an involved node showed no statistically significant 111 
relationship with ECS.  112 
Multivariate analysis 113 
On multivariate analysis, haziness in the adjacent fat showed an increased risk of ECS, with 114 
an odds ratio (OR) of 26.4 (1.2-594) as did increasing age of the patient with an odds ratio of 115 
1.24 (1-1.5) (table 2), that is an OR of 1.24 for each year older a patient is. The OR for 116 
haziness in the adjacent fat has a very wide confidence interval due to the small sample size: 117 
only 1 of 14 patients with haziness did not have ECS. 118 
 119 
120 
Discussion  121 
The aim of this study was to assess the accuracy of contrast-enhanced CT (CECT) to detect 122 
ECS and determine which radiological and clinicopathological features were most predictive 123 
of this in patients with head and neck cancer of unknown primary. This analysis contains a 124 
novel and homogenous cohort of patients, where extracapsular spread is known to be a 125 
significant predictor of survival. This study demonstrates that nodal longest diameter 126 
≥30mm, haziness in the surrounding fat on pre-operative CECT, increasing age and more 127 
advanced pathological nodal stage were statistically significant predictors of ECS.  This is the 128 
first paper to demonstrate these findings in this patient subdivision.   129 
UPHNSCC and ECS 130 
Head and neck squamous cell cancer of true unknown primary represents only 2-9% of all 131 
head and neck cancers9. This is a fairly unique group of patients in whom there is neither T 132 
stage of the primary tumour nor resection margin information to direct treatment and 133 
predict outcome.  There are no randomised controlled trials assessing the optimal 134 
management of UPHNSCC, therefore there is no standard treatment model. Guidelines 135 
suggest the approach should be curative with the least morbidity to the upper aerodigestive 136 
tract as possible. This could be single or combined modality treatment depending on the 137 
extent of the disease.  The addition of chemotherapy to adjuvant radiotherapy should be 138 
considered in N1 disease and above, if there is ECS.  The escalation of treatment to tri-139 
modality in patients with ECS has potentially significant treatment morbidity without 140 
necessarily improved outcomes compared to chemoradiation alone therefore detection of 141 
ECS pre-treatment can help guide management decisions.  142 
Imaging features and ECS 143 
In this cohort, haziness in the fat around the involved node was a highly significant predictor 144 
of ECS (OR 26.4). This increased density and stranding in the surrounding low density fat, 145 
which can range from subtle to marked, presumably relates to macroscopic extranodal 146 
spread of disease. Aiken et. al. found perinodal stranding to be marginally statistically 147 
significant for ECS with p 0.0553. Furthermore, maximum diameter as assessed on CECT  148 
30mm was also significantly associated with ECS.  The strong association between ECS and 149 
size (assessed clinically) was first reported over 30 years ago by Carter et al who reported 150 
that nodal masses greater than 3 cm   were more likely to have “trans-capsular” spread12. 151 
Reviewing comparable literature, several findings have been shown to help predict ECS 152 
radiologically, with mixed groups of patients (Table 3). These are predominantly from 153 
studies of oral cavity SCC. One of the difficulties with heterogenous series is that there is 154 
wide biological modulation between different head and neck subsites. HPV-positive 155 
oropharyngeal cancer contrasts with HPV-negative carcinoma of the larynx, for example.   156 
The most common predictor of ECS in previously published papers has been central node 157 
necrosis yet this current series did not demonstrate this. Both Randall et al and Aiken et. al. 158 
found that central nodal necrosis was an independent predictor of ECS, however only oral 159 
cavity SCC patients were studied 3,4. A consideration is the prevalence of high risk-HPV 160 
positivity in patients with UPHNSCC, reported as ranging from 22-52%13 and the fact that 161 
cystic nodes are particularly recognised with HPV-related head and neck squamous cancers. 162 
An earlier study established strong association with HPV tonsillar cancer and cystic cervical 163 
nodal metastases14. HPV data for this cohort is incomplete but contains 50% of patients with 164 
HR-HPV positive SCC.  Our criteria for nodal necrosis on CECT was the presence of central 165 
fluidic density. It is quite feasible that there is overlap between truly cystic and genuinely 166 
necrotic nodes on imaging, which is a histopathological distinction. CT has limited ability to 167 
distinguish internal necrotic debris from cystic change and HPV-related cystic nodes are 168 
potentially more represented here compared to an oral cavity SCC group.  169 
Our sensitivity is higher than many reported series although specificity is lower.  Awareness 170 
of the previously published findings in relation to perceived necrosis may have skewed the 171 
decision of both observers to denote ECS positivity with all but 2 levels having central 172 
low/fluid density in the relevant node, theoretically increasing false positives and 173 
diminishing specificity.  174 
Combining several imaging parameters for example 3 cm and haziness in the fat in ECS 175 
prediction could improve the specificity but at the possible expense of sensitivity. MRI and 176 
PET-CT have similarly been explored in relation to predicting ECS.  MRI has reported 177 
sensitivities of 50-80% and specificities of 85-100% depending on the imaging parameters 178 
used15,16 while predictive values of SUV max on PET/CT have shown conflicting results17,18.  179 
Currently, contrast-enhanced CT scanning is the most efficient and effective diagnostic 180 
modality for ECS assessment.  A large study of 508 patients19 observed that CT had higher 181 
accuracy versus MRI for extranodal extension at 80% vs 68% although this was not 182 
statistically significant. Interestingly, in their study when the imaging to surgery interval 183 
was >8 weeks the accuracy of scanning overall fell from 73% to 48%. 184 
Clinical features and ECS 185 
Increasing age was a predictive factor for ECS in this series, a new finding in UPHNSCC.  186 
HNSCC most commonly presents in the seventh decade and increasing age has been shown 187 
to be a relevant prognostic factor for overall survival.  Halmos et al demonstrated that older 188 
patients (>80 yrs) are less likely to receive tri-modality treatment and in our practice, 189 
patients over the age of 70 do not currently receive chemotherapy due to the lack of 190 
evidence to support improved survival. They are overall more likely to be managed with 191 
palliative intent for which ECS may be taken into account when making such a decision at 192 
the MDT20.   193 
Pathology features and ECS 194 
The nodal status of any head and neck cancer is a significant predictor for disease specific 195 
and overall survival including UPHNSCC.  We demonstrated, as expected, that pN2/3 was 196 
significantly more likely to predict ECS compared to N1. Nodal status has frequently been 197 
shown to be a reliable predictor of ECS and therefore this parameter has the potential to 198 
guide treatment decisions. However pathological nodal status is of course only available 199 
post-operatively. 200 
TNM  201 
Such is the importance of ECS in prognosis, the AJCC/UICC TNM 8th edition has incorporated 202 
clinical evidence of extranodal extension (ENE) into the staging of p16-negative 203 
oropharyngeal and hypopharyngeal SCC patients. However, a high bar for inclusion is 204 
recommended22 and stage migration must be avoided if possible with ECS not over-called 205 
radiologically. Since the introduction of TNM 8th edition, our practice is to report ECS and 206 
make note of it in the MDT setting. This can guide treatment decisions but correlation with 207 
clinical findings is advised prior to formally upstaging p16 negative oropharyngeal and 208 
hypopharyngeal SCC patients. 209 
Limitations 210 
Published series report low intra and inter observer agreement on the assessment of 211 
pathological ECS24 and indeed there is no internationally agreed standardisation, which has 212 
been called for25.   This would greatly improve comparison between studies.  213 
Potential weaknesses of this multicentre study include the small sample size however 214 
UPHNSCC represents a minority of head and neck cancers making it difficult to analyse a 215 
large sample size of this patient subset. Nonetheless it is a novel cohort. It could be of value 216 
to perform a similarly designed larger study in oral cavity SCC where the findings could be 217 
extrapolated to p16 negative oropharyngeal SCC where ECS is considered of more 218 
prognostic significance. 219 
 We do not have complete p16 or HR-HPV PCR data as at the time of diagnosis as this was 220 
not routinely tested in the early years of this dataset, although this is now done consistently 221 
in oropharyngeal and unknown primary HNSCC in line with the national head and neck 222 
cancer guidelines published in 201626.  223 
CECT was performed on a large range of scanners across a number of institutions. Despite 224 
this, a standardised protocol was applied, all scans were deemed diagnostically adequate 225 
and were able to be viewed in multiplanar reformat and this variability may increase the 226 
applicability of the findings to a wider group of UPHNSCC patients.  227 
  228 
We did not differentiate between microscopic and macroscopic ECS nor was the degree of 229 
ECS graded by severity histologically, rather a dichotomous outcome was determined from 230 
the pathology report summary. Regardless, our sensitivity was high and this would not have 231 
improved our specificity. The assessment of individual imaging parameters was done in 232 
consensus rather than individually as we felt this more reflected what is done in day to day 233 
practice and during MDT preparation. 234 
 235 
Conclusion 236 
This study demonstrates some novel findings for the prediction of extracapsular nodal 237 
spread in an unknown primary HNSCC cohort. The sensitivity was 81-85% although 238 
specificity was 46-54%. Interrater agreement was excellent. Nodal largest diameter ≥ 30 mm 239 
and increased pN status correlated with ECS. Haziness in the adjacent fat and increasing 240 
patient age were statistically significantly associated with ECS on both univariate and 241 
multivariate analysis.  Results are at variance with other published findings. This may reflect 242 
the cohort being observed, but also highlights the need for ongoing further larger studies. 243 
Radiological assessment for suspected ECS is beneficial for clinical decision making and 244 
valuable for prognostication and treatment planning, particularly in the unknown primary 245 
group where other parameters such as T stage and surgical margins are unavailable. 246 
Notwithstanding, care must be taken to avoid inappropriate stage migration in p16-negative 247 
oropharyngeal and hypopharyngeal SCC patients and escalation to multimodality therapy 248 
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 Table 1. Univariate analysis.  349 
 350 
 ECS positive 
N=23 
ECS negative  
N=8 
p value 
Size LD 30 
mm 
18 (78%) 2 (25%) 0.007 
Loss of sharp 
margin 
19 (83%) 4 (50%) 0.080 
Haziness in fat 13 (57%) 1 (13%) 0.023 
Necrosis 22 (96%) 8 (100%) 1.000 
Loss of fat 
plane  
23 (100%) 7 (86%) 0.258 
Age (yrs) 
Mean (SD) 
60 (7) 51 (7) 0.006 
Male  17 (74%) 6 (75%) 1.000 
pN2/3 (vs 
pN1) 
22 (96%) 3 (38%) 0.002 





Table 2. Multivariate analysis.   355 
 356 
Variable p value Odds ratio 
Age 0.002 1.24 (1-1.5) 
Haziness in Fat 0.009 26.4 (1.2-594) 
 357 
Figure Legends 358 
Figure 1 Axial (a) and Sagittal (b) contrast enhanced CT scan demonstrating loss of sharp margins –359 
arrows.  360 
Figure 2. axial (a) and sagittal (b) contrast enhanced CT scan demonstrating haziness in the adjacent 361 
fat – arrows 362 
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